Investigating the Potential of Isolating and Expanding Tumour-Infiltrating Lymphocytes from Adult Sarcoma

Ko, Anita; Coward, Victoria; Gökgöz, Nalan; Dickson, Brendan C.; Tsoi, Kim; Wunder, Jay S.; Andrulis, Irene L.

doi:10.3390/cancers14030548

Cited by 4 publications

(1 citation statement)

References 72 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They successfully propagated TILs from 70 STS surgical specimens, cocultured them with tumor cells, and expanded them using a rapid expansion protocol, observing that nearly all specimens generated TILs, mainly CD3+, which were responsive to the autologous tumor. Ko et al [ 193 ] published another preclinical study that suggests that certain sarcoma subtypes can potentially yield an appropriate number of cells for TIL therapy.…”

Section: Immunotherapy For Sarcoma: Clinical Resultsmentioning

confidence: 99%

Current Landscape of Immunotherapy for Advanced Sarcoma

Albarrán

Villamayor

Pozas

et al. 2023

Cancers

View full text Add to dashboard Cite

There is substantial heterogeneity between different subtypes of sarcoma regarding their biological behavior and microenvironment, which impacts their responsiveness to immunotherapy. Alveolar soft-part sarcoma, synovial sarcoma and undifferentiated pleomorphic sarcoma show higher immunogenicity and better responses to checkpoint inhibitors. Combination strategies adding immunotherapy to chemotherapy and/or tyrosine–kinase inhibitors globally seem superior to single-agent schemes. Therapeutic vaccines and different forms of adoptive cell therapy, mainly engineered TCRs, CAR-T cells and TIL therapy, are emerging as new forms of immunotherapy for advanced solid tumors. Tumor lymphocytic infiltration and other prognostic and predictive biomarkers are under research.

show abstract

Section: Immunotherapy For Sarcoma: Clinical Resultsmentioning

confidence: 99%

Current Landscape of Immunotherapy for Advanced Sarcoma

Albarrán

Villamayor

Pozas

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Gastric tubular adenocarcinoma with diffuse neutrophils infiltrating: characteristics and probable treatment strategy

Wang,

Zhu,

Wang

et al. 2023

Gastric Cancer

View full text Add to dashboard Cite

Radiation exposure assessment of nuclear medicine staff administering [177Lu]Lu-DOTA-TATE with active and passive dosimetry

Riveira-Martin,

Struelens,

Muñoz Iglesias

et al. 2023

EJNMMI Phys

View full text Add to dashboard Cite

Background The use of lutetium-177 (177Lu)-based radiopharmaceuticals in peptide receptor nuclear therapy is increasing, but so is the number of nuclear medicine workers exposed to higher levels of radiation. In recent years, [177Lu]Lu-DOTA-TATE has begun to be widely used for the treatment of neuroendocrine tumours. However, there are few studies evaluating the occupational radiation exposure during its administration, and there are still some challenges that can result in higher doses to the staff, such as a lack of trained personnel or fully standardised procedures. In response, this study aims to provide a comprehensive analysis of occupational doses to the staff involved in the administration of [177Lu]Lu-DOTA-TATE. Results A total of 32 administrations of [177Lu]Lu-DOTA-TATE (7.4 GBq/session) carried out by a physician and a nurse, were studied. In total, two physicians and four nurses were independently monitored with cumulative (passive) and/or real-time (active) dosemeters. Extremity, eye lens and whole-body doses were evaluated in terms of the dosimetric quantities Hp(0.07), Hp(3) and Hp(10), respectively. It was obtained that lead aprons reduced dose rates and whole-body doses by 71% and 69% for the physicians, respectively, and by 56% and 68% for the nurses. On average, normalised Hp(10) values of 0.65 ± 0.18 µSv/GBq were obtained with active dosimetry, which is generally consistent with passive dosemeters. For physicians, the median of the maximum normalised Hp(0.07) values was 41.5 µSv/GBq on the non-dominant hand and 45.2 µSv/GBq on the dominant hand. For nurses 15.4 µSv/GBq on the non-dominant and 13.9 µSv/GBq on the dominant hand. The ratio or correction factor between the maximum dose measured on the hand and the dose measured on the base of the middle/ring finger of the non-dominant hand resulted in a factor of 5/6 for the physicians and 3/4 for the nurses. Finally, maximum normalised Hp(3) doses resulted in 2.02 µSv/GBq for physicians and 1.76 µSv/GBq for nurses. Conclusions If appropriate safety measures are taken, the administration of [177Lu]Lu-DOTA-TATE is a safe procedure for workers. However, regular monitoring is recommended to ensure that the annual dose limits are not exceeded.

show abstract

Investigating the Potential of Isolating and Expanding Tumour-Infiltrating Lymphocytes from Adult Sarcoma

Cited by 4 publications

References 72 publications

Current Landscape of Immunotherapy for Advanced Sarcoma

Current Landscape of Immunotherapy for Advanced Sarcoma

Gastric tubular adenocarcinoma with diffuse neutrophils infiltrating: characteristics and probable treatment strategy

Radiation exposure assessment of nuclear medicine staff administering [177Lu]Lu-DOTA-TATE with active and passive dosimetry

Contact Info

Product

Resources

About